RxDoctor Payments Data

Krzysztof Kacprzak, MD

Internal Medicine · Webster, MANPI 1952364523

Payments from drug & device makers

$22,962in general payments, 2019–2025

Across 1,164 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • AbbVie$3K
  • Lilly USA, LLC$2K
  • Pfizer$2K
  • Amgen$2K
  • Novo Nordisk$1K
  • plus $10K from 49 others

What the payments were for

  • Food & beverage$22,849100%
  • Education$1130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca207$4,167
AbbVie(2 entities)132$2,587
Lilly USA, LLC87$1,726
Pfizer94$1,647
Amgen85$1,531
Novo Nordisk71$1,363
Boehringer Ingelheim55$1,164
Novartis47$939
Bayer40$720
Johnson & Johnson32$608
Astellas Pharma US Inc20$513
E.r. Squibb & Sons, L.L.C.23$489
Amarin Pharma, Inc.25$435
Abbott21$418
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC22$415
Exact Sciences15$320
GSK16$314
Sumitomo Pharma America, Inc.11$301
Merck18$277
Alnylam Pharmaceuticals Inc.11$262
Sanofi-aventis U.S. LLC13$253
Phathom Pharmaceuticals, Inc.10$208
Teva Pharmaceuticals USA, Inc.11$199
Nestle Healthcare Nutrition Inc.6$196
Esperion Therapeutics, Inc.10$188
Ardelyx, Inc.7$143
Dexcom, Inc.6$142
Biohaven Pharmaceutical Holding Company Ltd.6$134
Antares Pharma, Inc.6$132
Kowa Pharmaceuticals America, Inc.8$124
Sunovion Pharmaceuticals Inc.4$111
Idorsia Pharmaceuticals US Inc4$95
Mylan Specialty L.p.3$67
Lexicon Pharmaceuticals, Inc.3$67
Medtronic3$64
Redhill Biopharma Inc.3$61
Takeda Pharmaceuticals U.S.A., Inc.5$59
Scpharmaceuticals Inc.2$50
Bardy Diagnostics, Inc.2$40
Merz North America, Inc.1$40
Sanofi Pasteur Inc.2$38
Paratek Pharmaceuticals, Inc.2$37
Boston Scientific2$36
Genentech USA, Inc.2$31
Almatica Pharma LLC1$28
Vanda Pharmaceuticals Inc.1$27
Otsuka America Pharmaceutical, Inc.1$25
Madrigal Pharmaceuticals1$24
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$24
Kiniksa Pharmaceuticals, Ltd.1$23
Eisai Inc.1$23
Recordati_rare_diseases_inc.1$23
Urovant Sciences Inc1$19
Scilex Pharmaceuticals Inc.1$19
Altathera Pharmaceuticals LLC1$13

How this compares

$22,962 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$108,578
Medicare patients
174
Services billed
1,187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol102$108,303
EliquisApixaban60$69,920
OzempicSemaglutide45$55,781
JardianceEmpagliflozin45$53,123
MounjaroTirzepatide38$40,036
TrulicityDulaglutide30$35,658
Combivent RespimatIpratropium/Albuterol Sulfate24$16,585
Breo ElliptaFluticasone/Vilanterol25$11,034
SavellaMilnacipran Hcl12$10,094
MovantikNaloxegol Oxalate17$9,086
Tresiba Flextouch U-100Insulin Degludec14$7,876
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,657
Repatha SyringeEvolocumab14$7,628
Sildenafil Citrate13$7,462
Spiriva RespimatTiotropium Bromide12$6,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$4,167$118,793128 claims
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat$1,164$75,88981 claims
Lilly USA, LLCMounjaro, Trulicity$1,726$75,69468 claims
PfizerEliquis$1,647$69,92060 claims
Novo NordiskOzempic$1,363$55,78145 claims
GSKBreo Ellipta$314$11,03425 claims
AbbVieSavella$2,587$10,09412 claims
Redhill Biopharma Inc.Movantik$61$9,08617 claims
Sanofi-aventis U.S. LLCLantus$253$1,76413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Webster

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →